Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma to Present at LD Micro Conference
SOLANA BEACH, Calif. , Nov. 25, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Thursday, December 4, 2014 at 11:30AM PT at the LD Micro Main Event VII
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2014 Results
SOLANA BEACH, Calif. , Nov. 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2014 .
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
SOLANA BEACH, Calif. , Nov. 6, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2014 on Thursday, November 13,
View HTML
Toggle Summary Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
SOLANA BEACH, Calif. , Sept. 9, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead
View HTML
Toggle Summary Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
SOLANA BEACH, Calif. , Sept. 4, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer , CEO, will present a corporate overview at the Aegis Capital Corp.
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2014 Results
SOLANA BEACH, Calif. , Aug. 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014 .
View HTML
Toggle Summary Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001
SOLANA BEACH, Calif. , Aug. 12, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001,
View HTML
Toggle Summary Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
SOLANA BEACH, Calif. , July 30, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13,
View HTML
Toggle Summary Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank
SOLANA BEACH, Calif. , May 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has secured a $4.5 million term loan agreement with Square 1 Bank (Nasdaq:SQBK).
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2014 Results
SOLANA BEACH, Calif. , May 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2014 .
View HTML